Sickle cell disease (SCD) is associated with significant mortality and morbidity, especially in low- and middle-income countries.

We determined the indications for hospitalisation and predictors of 30-day re-admission among patients with SCD in Northern and Central Uganda.

Retrospective chart review.

Mulago National Referral Hospital in Kampala, St. Mary’s Hospital Lacor in Gulu and Gulu Regional Referral Hospital in Gulu, Uganda.

Patients with confirmed SCD admitted between January 2020 and January 2025 were included.

Primary outcome: indication for hospitalisation. Secondary outcomes: rate and predictors of 30-day hospital re-admission. Socio-demographic, clinical history and hospitalisation data were extracted using a pretested data extraction tool.

We enrolled 505 patients, accounting for 714 hospital admissions, with a mean age of 8.1±6.2 years. Most participants (n=489, 96.8%) had less than four admissions per year, with a median of 1 admission (IQR: 0–2). The most common indications for hospitalisation were infection (n=375, 52.5%), painful crisis (n=366, 51.3%) and anaemia (n=186, 26.1%). Malaria was the most prevalent infection (n=244, 65%). The median length of hospital stay was 4 days (IQR: 3–6), with a 30-day re-admission rate of 6.9% (n=49). Admission with painful crisis (adjusted OR (AOR): 0.45, 95% CI: 0.23 to 0.89, p=0.021), receiving a blood product (AOR: 0.32, 95% CI: 0.16 to 0.66, p=0.002) and having four or more admissions per year (AOR: 0.84, 95% CI: 0.04 to 0.17, p

Infections, especially malaria, and painful crises were the leading causes of hospitalisation among Ugandan patients with SCD. Frequent admissions, painful crises and blood transfusions were associated with lower 30-day re-admission risk. There is an urgent need to strengthen malaria prevention strategies and optimise access to disease-modifying therapy, such as hydroxyurea, to improve patient outcomes.

To assess predictors of timely transition to adult diabetes care among individuals diagnosed with type 1 diabetes during childhood and adolescence. We hypothesised that older age at the last paediatric visit and urban residency would be predictors of timely transition.

Retrospective cohort study using healthcare administrative data in a jurisdiction with a universal healthcare system.

2045 adolescents and young adults diagnosed with type 1 diabetes between the ages of 0.5 and 18 years.

We ascertained age at the last paediatric diabetes visit (LPDV), age at the first adult diabetes visit (FADV) and transition duration, defined as the time between LPDV and FADV. Timely transition was defined as a transition duration of

Only 31.3% of individuals saw an adult provider within 1 year of their LPDV. Each 1-year increase in the age at LPDV was associated with increased odds of timely transition (adjusted OR 1.82, 95% CI 1.71 to 1.93, p0.05).

Older age at the LPDV and urban residency are associated with increased odds of timely transition. Interventions should be developed to help keep adolescents engaged in paediatric care until an older age before referring them to adult diabetes care. Limitations of this study include unmeasured confounding and limited generalisability to non-universal healthcare systems.

The New York City (NYC) HIV Care Coordination Programme (CCP) is designed to help people with HIV (PWH) overcome barriers to care and treatment engagement. We assessed preferences for CCP components among programme enrollees (’clients’) and providers. Our objective is to compare client and provider preferences, which were previously analysed separately.

We used a discrete choice experiment to assess preferences for four CCP features (‘attributes’): Help with Adherence to Antiretroviral Therapy (ART), Help with Primary Care Appointments, Help with Issues other than Primary Care and Where Programme Visits Happen. Each of these attributes had 3–4 variants (‘levels’). In the original surveys, levels within Where Programme Visits Happen varied by participant type (client vs provider). We recoded the levels by visit location (VL) or by travel time (TT) to make them comparable and report results from both approaches.

25 Ryan White Part A-funded NYC CCPs participated.

152 providers and 181 clients completed the survey.

Preferences were quantified using the relative importance of the attributes and utility of the levels.

From January 2020 to March 2021, 152 providers and 181 clients completed the survey. Most of the providers (52%) were

Client and provider preferences clearly diverged regarding CCP service intensity: in the aggregate, clients tended to prefer lower-intensity services, whereas providers endorsed higher-intensity services. These results highlight the importance of engaging clients as partners in decisions about programme services to facilitate alignment with client values.

This study aims to identify factors that influence the role of community pharmacy teams in preventing prescription and over-the-counter (OTC) opioid misuse.

Qualitative design using interviews; thematic analysis was used to generate themes mapped to the Capability, Opportunity and Motivation Behaviour (COM-B) model.

Community pharmacies in North East England.

28 community pharmacy staff including 16 pharmacists, 1 pharmacy assistant, 10 dispensers and 1 pharmacy technician.

Factors related to the capability component include communication skills, ability to identify service users who misuse OTC opioids, and education and training. Factors in the opportunity component include staff and funding, tools for identification and referral of service users at risk of opioid misuse, and relationship with other healthcare professionals. For the motivation component, attitude towards role, attitude of pharmacist or pharmacy manager, perception about commissioners and commissioned services, and attitude towards service users were identified.

This study identified factors that could influence community pharmacists’ roles in opioid misuse. A critical factor influencing community pharmacy teams preventing opioid misuse is access to a single system to record the use of both OTC and prescription opioids. This would enable teams to identify service users misusing or at risk of misusing opioids, while supporting staff education and training and regulatory compliance. Future research should focus on developing interventions using these identified factors to enhance community pharmacists’ roles in opioid misuse prevention.